1.99
-2.45%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cryofocus Medtech (Shanghai) Co
Its shares trade on HKEX under the ticker 6922.HK. It has been listed since 30 December 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥95.3m and a net loss of CN¥38.2m. At that date it held total assets of CN¥137.5m and shareholders' equity of CN¥49.7m.
Cryofocus Medtech (Shanghai) Co. Ltd. manufactures cryoablation devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2022-12-30. The firm has built a comprehensive product portfolio comprising two core products, approximately 15 other product candidates in various development stages as well as approximately six additional commercialized medical consumables. The two core products comprise the Bladder Cryoablation System and the Endoscopic Clip for Anastomosis. The firm's products mainly target two therapeutic areas: natural orifice transluminal endoscopic surgery, to treat urinary, respiratory, and digestive diseases (such as bladder cancer, COPD, asthma, airway stenosis, gastric cancer, esophageal cancer and others), and vascular interventional therapy to treat cardiovascular diseases (such as atrial fibrillation, hypertension and others).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 30 Dec 2022
- Employees
- 384
- Website
- cryofocus.com ↗
Leadership
Pay as last reported
- Mr. Kejian LiExecutive Chairman of the Board, since 2013
- Mr. Wei LiuChief Financial Officer, Executive Director, Joint Company Secretary, Board Secretary, since 2020
- Mr. Jun ZhuGeneral Manager, Executive Director, since 2020CN¥7.5m
- Mr. Thach Buu DuongDeputy General Manager
- Mr. Yulong LiuVice General Manager
- Mr. Zhimin ChenExecutive Vice President of Ningbo SensCure
- Mr. Yuepeng DiaoDeputy Vice President
- Dr. Jihong QuChief Medical Officer
- Dr. Kuiwen ZhaoTechnical Director, Research and Development Manager
- Ms. Wai Yan LeungJoint Company Secretary
- Mr. Shiwen LvNon-Executive Director
- Mr. Chunsheng ZhaoNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cryofocus Medtech (Shanghai) Co Ltd employs 384 full-time employees in Shanghai.
- The company has two core products: Bladder Cryoablation System and Endoscopic Clip for Anastomosis.
- Cryofocus Medtech targets urinary, respiratory, and digestive diseases with its products.
Weaknesses
- The company has only two core products in its comprehensive portfolio.
- Cryofocus Medtech has approximately 15 product candidates in various development stages.
- The firm's products mainly focus on two therapeutic areas: natural orifice transluminal endoscopic surgery and vascular interventional therapy.
Opportunities
- Cryofocus Medtech has approximately six additional commercialized medical consumables in its portfolio.
- The company's product portfolio targets urinary, respiratory, and digestive diseases including bladder cancer and gastric cancer.
- Cryofocus Medtech's products address cardiovascular diseases such as atrial fibrillation and hypertension.
Threats
- Cryofocus Medtech's business is limited to Shanghai as its headquarters city.
- The company's IPO was on 30 December 2022, which may affect its market position.
- Cryofocus Medtech has no mention of international expansion in its business description.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.